MiDx has developed a lateral flow device (RPaD) for the detection of a major bacterial lung infection using unique patented biomarkers found in urine. This market is a $0.5 billion diagnostic detection area. We are able to detect these infections caused by the bacterium Pseudomonas aeruginosa in people with chronic underlying illnesses e.g., Cystic Fibrosis (CF) and Chronic Obstructive pulmonary disorder (COPD) and other lower respiratory tract infections (LRTIs). Our device is registered with the MHRA and is undergoing single centre performance evaluation and feasibility with device optimisation and scale up manufacturing to follow. The device will integrate with the existing care pathway and after regulatory approval will be suitable for clinical and home use. Health economics have demonstrated a highly favourable cost benefit to the NHS.
